Congleton Jon 4
4 · Mineralys Therapeutics, Inc. · Filed Nov 13, 2025
Insider Transaction Report
Form 4
Congleton Jon
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
2025-11-11$41.64/sh−12,806$533,235→ 818,499 total - Sale
Common Stock
2025-11-11$43.50/sh−4,000$173,984→ 805,637 total - Sale
Common Stock
2025-11-11$45.83/sh−112,275$5,145,956→ 664,155 total - Sale
Common Stock
2025-11-11$46.89/sh−32,850$1,540,212→ 631,305 total - Sale
Common Stock
2025-11-11$42.31/sh−8,862$374,947→ 809,637 total - Sale
Common Stock
2025-11-11$45.20/sh−29,207$1,320,165→ 776,430 total
Footnotes (6)
- [F1]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.0500 to $42.0000. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
- [F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.0500 to $43.0400. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
- [F3]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.1700 to $44.0500. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
- [F4]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.4800 to $45.4297. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
- [F5]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.4300 to $46.4200. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.
- [F6]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.4400 to $47.4191. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (6) to this Form 4.